未登录

A

Amita Datta-Mannan

Eli Lilly and Company

H指数:21

被引数:1,641

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacokinetic Drug–Drug Interactions of Imlunestrant in Healthy Female Participants of Nonchildbearing Potential

Imlunestrant在无生育能力的健康女性参与者中的药代动力学药物-药物相互作用

CTS-Clinical and Translational Science

IF2.8

2026-09-200

OAAI

Phase 1 Study Evaluating the Effect of Food and Omeprazole-Induced Gastric pH Change on the Pharmacokinetics and Safety of Imlunestrant in Healthy Females

I期研究评估食物和奥美拉唑诱导的胃pH变化对健康女性中伊鲁美斯特兰药代动力学和安全性的影响

Clinical Therapeutics

IF3.6

2025-11-210

OAAI

Evaluation of Pharmacokinetics of Lebrikizumab in Healthy Individuals After Subcutaneous Administration Using a Prefilled Syringe or Autoinjector in a Phase 1 Randomized Study

CLINICAL THERAPEUTICS

IF3.6

2025-01-010

PRE

Identification of a Safe and Tolerable Carbamazepine Dosing Paradigm that Facilitates Effective Evaluation of CYP3A4 Induction

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-06-120

OAAI

Advancing the utilization of real-world data and real-world evidence in clinical pharmacology and translational research-Proceedings from the ASCPT 2023 preconference workshop

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2024-04-041

OAAI

Impact of COVID-19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-03-270

OAAI

Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL-17A (LY3509754): A Phase I Randomized Placebo-Controlled Study

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-01-318

OAAI

Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2023-07-2915

OAAI

Monoclonal Antibody Pharmacokinetics in Cynomolgus Monkeys Following Subcutaneous Administration: Physiologically Based Model Predictions from Physiochemical Properties

皮下给药后食蟹猴中的单克隆抗体药代动力学: 基于生理化学特性的生理模型预测

IF3.7

2022-12-014

PRE

Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties

IF7.3

2022-05-0117

OAAI

Pharmacokinetic Developability and Disposition Profiles of Bispecific Antibodies: A Case Study with Two Molecules

IF2.7

2021-12-289

OAAI

Influence of FcRn binding properties on the gastrointestinal absorption and exposure profile of Fc molecules

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2021-02-019

PRE

Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies

IF7.3

2020-06-0339

OAAI

Antibody Conjugates-Recent Advances and Future Innovations

IF2.7

2020-01-0891

OAAI

A novel molecule with profound tumor killing activity

CANCER RESEARCH

IF16.6

2019-07-010

PRE

The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass

IF3.7

2018-09-2515

OAAI

Engineered FcRn Binding Fusion Peptides Significantly Enhance the Half-Life of a Fab Domain in Cynomolgus Monkeys

BIOTECHNOLOGY JOURNAL

IF3.1

2018-06-269

PREAI

Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys

IF7.3

2016-04-2541

OAAI

The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies

非特异性结合，靶标介导的清除和FcRn相互作用对人源化抗体药代动力学的相互作用

IF7.3

2015-09-0479

OAAI

Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics

在不影响pI的情况下平衡人源化mab的互补决定区中的电荷减少了非特异性结合并改善了药代动力学

IF7.3

2015-02-19127

OAAI